Adapt Pharma parent Emergent BioSolutions has revealed how it plans to defend the company’s Narcan (naloxone) nasal spray against looming generic competition in the US, including through an authorized generic deal with a major generics firm, as it awaits a verdict from an appeals court in litigation with Teva.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?